Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study Ceftolozane-Tazobatam for febrile neutropenia

Main Article Content

Francesco Marchesi
Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy Tel: +39 06 52665022 Fax: +39 06 52662849 E-mails: ; fmarchesi@ifo.it

Fabrizio Ensoli
IRCCS San Gallicano Dermatological Institute

Irene Terrenato
IRCCS Regina Elena National Cancer Institute

Elena Papa
IRCCS Regina Elena National Cancer Institute

Fulvia Pimpinelli
IRCCS San Gallicano Dermatological Institute

Grazia Prignano
IRCCS San Gallicano Dermatological Institute

Antonio Spadea
IRCCS Regina Elena National Cancer Institute

Ilaria Cavallo
IRCCS San Gallicano Dermatological Institute

Enea Gino Di Domenico
IRCCS San Gallicano Dermatological Institute

Luigi Toma
IRCCS Regina Elena National Cancer Institute

Andrea Mengarelli
IRCCS Regina Elena National Cancer Institute

Keywords

Ceftolozane-Tazobactam, febrile neutropenia, hematologic malignancy, carbapenem-sparing

Abstract

NA

Downloads

Download data is not yet available.


Abstract 7481
PDF Downloads 546
HTML Downloads 160

References

1. Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, et al; SEIFEM Group. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97:1717-1726. doi: 10.1007/s00277-018-3341-6.
2. Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, et al; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI). Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin Infect Dis. 2017;65:1884-1896. doi: 10.1093/cid/cix690.
3. Verlinden A, Mikulska M, Knelange NS, Averbuch D, Styczynski J; Infectious Diseases Working Party (IDWP) of the European Group for Blood and Marrow Transplantation Group (EBMT) Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant. 2020 Feb 11. doi: 10.1038/s41409-020-0811-y [Epub ahead of print].
4. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign:International guidelines for management of sepsis and septic shock, 2016. Intensive Care Med. 2017;43:304-377. doi: 10.1007/s00134-017-4683-6.
5. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051. doi: 10.1200/JCO.2000.18.16.3038.
6. Marchesi F, Cattaneo C, Criscuolo M, Delia M, Dargenio M, Del Principe MI, et al.; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group. A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: a prospective multicenter study of the SEIFEM group. Am J Hematol. 2019;94:1104-1112. doi: 10.1002/ajh.25585.
7. Di Domenico EG, Rimoldi SG, Cavallo I, D'Agosto G, Trento E, Cagnoni G, et al. Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis. BMC Microbiol. 2019;19:228. doi: 10.1186/s12866-019-1596-2.
8. Karaiskos I, Giamarellou H. Carbapenem-sparing strategies for ESBL producers: when and how? Antibiotics. (Basel) 2020;9. doi: 10.3390/antibiotics9020061.
9. Corcione S, Lupia T, Maraolo AE, Mornese Pinna S, Gentile I, et al. Carbapenem-sparing strategy: carbapenemase, treatment, and stewarship. Curr Opin Infect Dis. 2019;32:663-673. doi: 10.1097/QCO.0000000000000598.
10. Fernández-Cruz A, Alba N, Semiglia-Chong MA, Padilla B, Rodríguez-Macías G, Kwon M, et al. A case-control study of real-life experience of ceftolozane-tazabactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2019;63(2):e02340-18. doi: 10.1128/AAC.02340-18.

Article Sidebar

PDF HTML
Published
Sep 7, 2020
DOI https://doi.org/10.4084/mjhid.2020.065

Article Details

How to Cite

Marchesi, F. (2020) “Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study: Ceftolozane-Tazobatam for febrile neutropenia”, Mediterranean Journal of Hematology and Infectious Diseases, 12(1), p. e2020065. doi: 10.4084/mjhid.2020.065.
Issue
Vol. 12 No. 1 (2020): Mediterranean Journal of Hematology and Infectious Diseases, Volume 12, 2020
Section
Scientific Letters
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.